Presenter of 6 Presentations
Recent therapeutic options for LDL-C management (ID 1636)
Moderator Led Q&A (ID 1648)
Anitschkow Lecture: Personalised Prevention of Atherosclerotic Cardiovascular Disease (ID 1417)
Panel discussion and Q&A (ID 1639)
Cholesterol Roundtable case study (ID 1420)
O065 - IMPACT OF BEMPEDOIC ACID ON CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS WITH STATIN INTOLERANCE: THE CLEAR OUTCOMES STUDY (ID 1533)
Abstract
Background and Aims
Aim: The ATP citrate lyase inhibitor, bempedoic acid, has been demonstrated to reduce low-density lipoprotein (LDL) cholesterol, but is effect on cardiovascular outcomes has not been previously studied.
Methods
Methods: 13,970 patients at high cardiovascular risk, LDL-C >100 mg/dL and documented statin intolerance were treated with bempedoic acid 180 mg or matching placebo daily for at least 24 months. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, or coronary revascularization.
Results
Results: Bempedoic acid produced greater lowering of LDL-cholesterol (21.1 vs 0.6) from a baseline of 139 mg/dL. Less primary endpoint events were observed in the bempedoic acid group (11.7 vs 13.3%, hazard ratio (HR) 0.87, 95% CI 0.79 to 0.96, P=0.004). Bempedoic acid treated patients also demonstrated a lower rate of (1) the composite of cardiovascular death, myocardial infarction or stroke (8.2 vs 9.5%, HR 0.85, 95% CI 0.76 to 0.96, P=0.006), (2) myocardial infarction (3.7 vs 4.8%, HR 0.77, 95%, CI 0.66 to 0.91, P=0.002) and (3) coronary revascularization (6.2 vs 7.6%, HR 0.81, 95% CI 0.72 to 0.92, P=0.001). No difference was observed between groups with regard to myalgia (5.6 vs 6.8%), while bempdoic acid treated patients were more likely to experience gout (3.1% vs. 2.1%), cholelithiasis (2.2% vs 1.2%), and small increases in serum creatinine, uric acid and hepatic enzymes.
Conclusions
Conclusions: Lowering levels of LDL-cholesterol with bempedoic acid associated with reductions in the rate of cardiovascular events in patients with statin intolerance.